

Pemphigoid Gestationis

Michael Niechayev, BS* and Lauren Sylwanowicz, MD*

*University of California, Irvine, Department of Emergency Medicine, Orange, CA

Correspondence should be addressed to Michael Niechayev, BS at mniechay@uci.edu

Submitted: July 26, 2018; Accepted: September 9, 2018; Electronically Published: October 15, 2018; <https://doi.org/10.21980/J8MG9D>

Copyright: © 2018 Niechayev, et al. This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) License.

See: <http://creativecommons.org/licenses/by/4.0/>



History of present illness: A 40-year-old female presented to the emergency department reporting a pruritic pustular rash that began on her abdomen five weeks prior. Since onset, the rash spread to her extremities, chest, and face. At presentation, she was three weeks post-partum and reported subsequent worsening of the rash, with the development of blisters on her abdomen and extremities immediately following her delivery.

Significant findings: Physical exam findings were significant for 1-3 cm diameter well-demarcated superficial ulcers on the patient's abdomen and extremities, with mucosal sparing. Several small tense bullae were present on the bilateral inner thighs and numerous small reddish plaques were scattered over the patient's back. Nikolsky's sign was negative. No lymphadenopathy was noted.

Discussion: Pemphigoid gestationis (PG) is a rare autoimmune disease caused by immunoglobulin G1 (IgG1) autoantibodies directed against collagen XVII, a glycoprotein located at the skin's basement membrane.¹ The damage these antibodies cause to the basement membrane results in a characteristically pruritic, blistering rash that typically spares the mucous membranes.¹ PG has an incidence of 1 in 10,000 to 60,000 pregnancies, but can also rarely arise as a paraneoplastic manifestation of trophoblastic tumors.² PG most often presents in the second or third trimester of pregnancy, though it may also occur in the post-partum period, and carries a high risk of recurrence with subsequent pregnancies.^{1,3}

Diagnosis is based on a combination of clinical findings, skin biopsy, and enzyme-linked immunosorbent assay.^{3,4} The goal in treating PG is to decrease blister formation and relieve pruritus. However, no randomized controlled trials for the treatment of PG have been published given the rarity of the disease, and treatment recommendations are based on studies of similar skin diseases.¹ Topical corticosteroids often serve as first-line treatment, given their relative safety during pregnancy, and oral antihistamines are often added to further reduce pruritus.¹ For more severe cases, systemic corticosteroids can be used in the treatment of PG.^{3,5} Lastly, while fetal prognosis is generally good, PG is linked to an increased risk of prematurity and fetal growth restriction, and patients should be encouraged to receive close monitoring from an obstetrician.^{1,5,6}

The patient described in this case remained stable during hospitalization, and a diagnosis of PG was confirmed by direct immunofluorescence of a perilesional punch biopsy. The patient was discharged on an oral prednisone taper in addition to topical triamcinolone 0.1% cream and oral diphenhydramine. At a follow-up appointment with dermatology one month after discharge, the patient demonstrated significant improvement. No blisters were visible on the patient's skin, though the patient reported mild pruritus and demonstrated multiple erythematous macules and patches.

Topics: Pemphigoid gestationis, pruritic urticarial papules and plaques of pregnancy, direct immunofluorescence, ELISA (enzyme-linked immunosorbent assay), autoimmune bullous diseases.

References:

1. Huilaja L, Mäkikallio K, Tasanen K. Gestational pemphigoid. *Orphanet J of Rare Diseases*. 2014;9:136. doi:10.1186/s13023-014-0136-2

2. Roger D, Vaillant L, Fignon A, Pierre F, Bacq Y, Brechot JF, et al. Specific pruritic diseases of pregnancy: a prospective study of 3192 pregnant women. *Arch Dermatol*. 1994;130(6):734–739. doi:10.1001/archderm.1994.01690060064006
3. Jenkins RE, Hern S, Black MM. Clinical features and management of 87 patients with pemphigoid gestationis. *Clin Exp Dermatol*. 1999;24(4):255-259. doi:10.1046/j.1365-2230.1999.00472.x
4. Powell AM, Sakuma-Oyama Y, Oyama N, Albert S, Bhogal B, Kaneko F, et al. Usefulness of BP180 NC16a enzyme-linked immunosorbent assay in the serodiagnosis of pemphigoid gestationis and in differentiating between pemphigoid gestationis and pruritic urticarial papules and plaques of pregnancy. *Arch Dermatol*. 2005;141(6):705–710. doi:10.1001/archderm.141.6.705
5. Kushner CJ, Concha JS, Werth VP. Treatment of autoimmune bullous disorders in pregnancy. *Am J Clin Dermatol*. 2018;19(3):391-403. doi: 10.1007/s40257-018-0342-0
6. Chi C, Wang S, Holmes RC, Ambros-Rudolph C, Powell J, Jenkins R, et al. Pemphigoid gestationis: early onset and blister formation are associated with adverse pregnancy outcomes. *British J of Dermatol*. 2009;160(6):1222-1228. doi:10.1111/j.1365-2133.2009.09086.x